FIELD: immunotherapy.
SUBSTANCE: group of inventions relates to the field of immunotherapy and can be used to increase the antitumor activity of NK-cells and T-lymphocytes in the treatment and prevention of lung cancer, leukemia, cancer of viral etiology and other oncological diseases. Proposed is a method for activating cytotoxic lymphocytes by treating blood cells with a peptide containing amino acid sequence His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID No.1), or its pharmacologically acceptable salts in a concentration that enhances the ability of cytotoxic lymphocytes to lyse transformed body cells, such as cancer cells or virus-infected cells. The method increases the expression of activation receptors CD25, CD69, NKG2D, CD226 CD244 and NKp80 on the surface of lymphocytes and reduces the expression of inhibitory receptors KIR2DL3, KIR3DL1, KLRG1, also increases the sensitivity of lymphocytes to IL-2 and IL-12, stimulates the production of IFNγ, maintains populations of NK-cells in a functionally active state during cytotoxic reaction with transformed cells.
EFFECT: method can be used in combination with IL-2 or IL-12 to enhance their antitumor effect. Activation of lymphocytes by the proposed method increases the number of tumor target cells with injuries from 13.5 to 73%.
20 cl, 12 dwg, 14 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF CYTOGENETIC ACTIVATION OF HUMAN LYMPHOCYTES | 2015 |
|
RU2603079C2 |
METHOD OF TREATING ONCOLOGICAL PATIENTS WITH CYTOTOXIC LYMPHOCYTES | 2015 |
|
RU2596505C1 |
METHOD FOR ACTIVATING CYTOTOXIC T-LYMPHOCYTES IN A POPULATION OF BLOOD MONONUCLEAR CELLS USING MEMBRANE VESICLES OBTAINED FROM GENETICALLY MODIFIED TUMOR CELLS OF M14 MELANOMA WITH OVEREXPRESSION OF INTERLEUKIN 2 | 2022 |
|
RU2790867C1 |
METHOD FOR LONG-TERM CULTIVATION AND EXPANSION OF NK CELLS WITH HIGH VIABILITY AND FUNCTIONAL ACTIVITY | 2021 |
|
RU2794770C1 |
TLP-BASE IMMUNOGENIC COMPOSITION | 1997 |
|
RU2192274C2 |
BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
REPRODUCTION AND USE OF NON-HEMATOPOIETIC TISSUE-RESIDENT γδ T-CELLS | 2016 |
|
RU2784566C2 |
IMPROVED METHOD FOR INCREASING TUMOUR-RESPONSIVE T-LYMPHOCYTE COUNT IN IMMUNOTHERAPY OF ONCOLOGIC PATIENTS | 2006 |
|
RU2399382C2 |
ALLOPHERONES AS IMMUNOMODULATING PEPTIDES | 1999 |
|
RU2172322C1 |
METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
Authors
Dates
2021-07-19—Published
2019-09-10—Filed